Maladie
Leukaemia
ICD-10 : C91–C95 — Leukaemia
Chiffres clés
Valeurs publiées uniquement. Chaque tuile ouvre la section qui porte sa source, son année et sa référence.
- Fourchettes de coûts de traitement 25 fourchettes publiées, chacune avec sa source sur la page de la ligne
- Survie à cinq ans 30.6% 95% CI 30.2–31.1 · 2019–2021
- Hôpitaux disposant d’une source publiée 8 pour cette maladie, chacun avec sa source publiée
- Essais cliniques 150 en recrutement ou pas encore en recrutement, selon les publications
Détails de la maladie
- Nom anglais
- Leukaemia
Également appelé
- Leukaemia
- Leukemia
Fourchettes de coûts de traitement
Chaque fourchette ci-dessous est publiée sur une même base de facturation : Avant remboursement. Les sources ne publient aucun chiffre après remboursement ; aucun n'est donc affiché ici.
| Parcours de traitement | Fourchette de coûts | Base du prix | Année des données |
|---|---|---|---|
| Chimiothérapie | 20000 – 20000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 54000 – 54000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 95000 – 95000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 87000 – 87000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 100000 – 100000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 7000 – 7000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 9000 – 9000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 36000 – 36000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 10500 – 10500 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 42200 – 42200 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 52700 – 52700 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 95000 – 95000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 70800 – 70800 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 28000 – 28000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 11500 – 11500 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 66300 – 66300 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 20800 – 20800 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 36500 – 36500 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 30100 – 30100 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 50000 – 50000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 72000 – 72000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 30800 – 30800 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 43300 – 43300 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 72000 – 72000 CNY | Forfait par pathologie | 2020 |
| Chimiothérapie | 95400 – 95400 CNY | Forfait par pathologie | 2020 |
Les barres partagent une même échelle pour les lignes ci-dessus : chacune commence au chiffre inférieur publié de sa ligne et se termine à son chiffre supérieur. Le chiffre supérieur le plus élevé de cette page est 100000 CNY. Chaque ligne conserve son année de données et sa référence.
25 fourchettes de coûts pour cette maladie, chacune avec sa source sur la page de la ligne.
Les valeurs rédigées en chinois sont citées telles que publiées par la source.
Survie à cinq ans
Taux de survie à 5 ans 30.6% IC à 95 % 30.2–31.1
- Population
- Global (tous stades confondus) · Survie relative standardisée selon l’âge
- Période
- 2019–2021
- Éditeur
- Centre national du cancer
- Nature de la valeur
- Valeur estimée (analyse hybride)
- Périmètre du registre
- 281 registres du cancer de population
- Disponibilité des données par stade
- Non publié
Les valeurs rédigées en chinois sont citées telles que publiées par la source.
Comment lire ce chiffre. Ce chiffre est publié pour tous les stades confondus ; il s'agit donc d'une moyenne sur l'ensemble des personnes des données du registre national, non d'un pronostic pour une personne. Pour la plupart des cancers, le stade au diagnostic est le facteur unique le plus fort des différences de survie : la survie est généralement plus élevée lorsque le cancer est détecté à un stade précoce et plus faible lorsqu'il est détecté plus tard. Les comparaisons entre cancers dépendent aussi de la précocité ou de la tardiveté à laquelle chacun tend à être diagnostiqué ; un chiffre plus bas ne signifie donc pas en soi des soins moins bons.
Le chiffre est une survie relative : il compare les personnes diagnostiquées avec ce cancer à des personnes du même âge et du même sexe dans la population générale, et il est standardisé selon l'âge ; ce n'est donc pas la part de patients encore vivants après cinq ans. Il est publié comme valeur estimée (analyse hybride) car les rapports des registres arrivent avec un décalage ; le Centre national du cancer a donc modélisé la période la plus récente. Pour situer, la même source publie une survie relative à cinq ans de 43,7 % pour l'ensemble des cancers en 2019–2021.
Hôpitaux disposant d'un dossier publié pour cette maladie
Sélectionnés à partir de sources de données publiques officielles
Ces hôpitaux sont sélectionnés à partir de sources de données publiques officielles — les classements de réputation par spécialité de l'université Fudan, la liste des spécialités cliniques clés nationales et les centres nationaux de recherche clinique — afin que chaque ligne d'une fiche puisse être vérifiée dans sa source publiée. Il ne s'agit pas d'une inscription payante ou promue.
Comment ces hôpitaux ont été sélectionnés
Admission. Un hôpital est listé pour une maladie lorsque la spécialité à laquelle cette maladie est rattachée porte au moins l'un des éléments suivants : une place ou une nomination dans le classement de réputation par spécialité de l'université Fudan ; un titre de spécialité clinique clé nationale de niveau A, B ou C ; ou un centre national de recherche clinique ou un laboratoire clé d'État dans cette spécialité. L'accréditation JCI est affichée comme un badge ; elle ne détermine jamais l'admission et ne détermine jamais l'ordre.
Ordre. Étape 1 : une place Fudan entre 1 et 10 pour la spécialité. Étape 2 : une autre place Fudan, ou une nomination. Étape 3 : un titre de spécialité clinique clé nationale de niveau A. Étape 4 : un titre de spécialité clinique clé nationale de niveau B. Étape 5 : un centre national de recherche clinique ou un laboratoire clé d'État dans la spécialité, un centre avant un laboratoire. Étape 6 : un titre de spécialité clinique clé nationale de niveau C, qui est un enregistrement que nous publions sans source officielle indépendante et qui figure donc après les autres.
Égalités. Au sein d'une même étape : la meilleure place Fudan d'abord, puis le niveau de spécialité clé le plus fort (A avant B avant C), puis la province, puis la ville, puis le nom de l'hôpital — le même ordre province-ville-nom que celui utilisé par le répertoire des hôpitaux. Huit hôpitaux au maximum sont listés.
Lorsque la liste est courte. Cinq hôpitaux ou plus : les huit premiers sont listés. Trois ou quatre : tous sont listés, et un volet supplémentaire ajoute les autres enregistrements jusqu'à huit, chacun portant son niveau de preuve. Un ou deux : de même, avec ce volet ouvert et une ligne indiquant combien d'hôpitaux disposent d'un dossier public solide. Aucun : la page indique qu'aucun dossier public solide n'a été trouvé et renvoie au répertoire de la spécialité. Une place, un établissement ou un décompte ne sont jamais inventés pour remplir la liste.
Les classements Fudan sont le classement de réputation par spécialité le plus largement reconnu par les cliniciens chinois, publié chaque année par l'institut de gestion hospitalière de l'université Fudan.
-
West China Hospital, Sichuan University
Spécialité clinique clé nationale
- Hématologie (niveau A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Également classé : Chirurgie générale #3, Chirurgie thoracique #4, Urologie #2 (ex æquo) dans la liste Fudan.
-
Qilu Hospital of Shandong University
Spécialité clinique clé nationale
- Hématologie (niveau A) http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Également classé : Gynécologie #7 (ex æquo), Oto-rhino-laryngologie nommé, Gastro-entérologie nommé dans la liste Fudan.
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Spécialité clinique clé nationale
- Hématologie (niveau A) http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Également classé : Chirurgie générale #7, Urologie #9, Maladies infectieuses #2 dans la liste Fudan.
-
Ruijin Hospital
Spécialité clinique clé nationale
- Hématologie (niveau B) https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
Également classé : Chirurgie générale #4, Chirurgie thoracique #7 (ex æquo), Pneumologie #5 dans la liste Fudan.
-
Beijing Hospital
Spécialité clinique clé nationale
- Hématologie (niveau B) https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Également classé : Urologie nommé dans la liste Fudan.
-
Peking University People's Hospital
Spécialité clinique clé nationale
- Hématologie (niveau B) https://www.pkuph.cn/news_details/26715.html
Également classé : Chirurgie générale #10, Chirurgie thoracique #7, Gynécologie #7 dans la liste Fudan.
-
Peking University Third Hospital
Spécialité clinique clé nationale
- Hématologie (niveau B) https://www.puh3.net.cn/yygk/zdxk.htm
Également classé : Gynécologie #4, Urologie nommé, Gastro-entérologie nommé dans la liste Fudan.
-
Anhui Provincial Hospital
Spécialité clinique clé nationale
- Hématologie (niveau B) https://www.ahslyy.com.cn/nanqu/col456/892156
Également classé : Chirurgie générale nommé, Oto-rhino-laryngologie nommé dans la liste Fudan.
Essais cliniques (traitements expérimentaux)
En complément des soins standards, des études de recherche clinique sur Leukaemia peuvent actuellement être ouvertes aux participants en Chine. Les traitements à l'étude n'ont pas été approuvés par le régulateur comme traitement standard — il s'agit de recherche clinique, non de soins courants. Chaque fiche nomme l'investigateur principal et l'hôpital qui mène l'étude. Si cela vous intéresse, contactez l'hôpital pour vous renseigner sur l'éligibilité et décider vous-même de candidater.
-
Étude The Efficacy and Safety of BCL-2 Inhibitors Combined with the HyperCVAD Regimen in the Treatment of Newly Diagnosed T-lymphoblastic Leukemia/ Lymphoma
- Investigateur principal
- Xianmin Song, MD · Investigator Official Title
- Hôpital
- Shanghai General Hospital
- Statut
- En recrutement
- Registre
- NCT06598722
-
Étude To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06450067
-
Étude A Clinical Study Evaluating the Safety and Efficacy of IL-15-armored Novel CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia
- Investigateur principal
- FengYan Jin · Clinical Professor of Hematology Department
- Hôpital
- The First Hospital of Jilin University
- Statut
- En recrutement
- Registre
- NCT07509086
-
Étude Avapritinib Combined With Standard Therapy for the Treatment of Newly Diagnosed KIT Mutation Acute Myeloid Leukemia With t(8;21)(q22;q22.1); Inv(16)(p13.1q22) or t(16;16)(p13.1;q22): a Prospective, Multi-center, Single-arm, Two-cohorts Study
- Investigateur principal
- Chen Suning · Prof.
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07028073
-
Étude An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants With B-cell Acute Lymphoblastic Leukemia
- Hôpital
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Statut
- En recrutement
- Registre
- NCT06580301
145 études enregistrées supplémentaires
-
Étude A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT05091424
-
Étude Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in Pediatric Acute Myeloid Leukaemia: a Prospective Study
- Investigateur principal
- Chang Yingjun · Chief Physician
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06452732
-
Étude Venetoclax-Azacitidine in Combination With Chidamide and CAG Versus 3+7 Regimen in Fit Older Patients With Acute Myeloid Leukaemia：A Multicenter, Randomized, Controlled, Phase 3 Trial
- Investigateur principal
- Daihong Liu · Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital
- Hôpital
- Chinese PLA General Hospital
- Statut
- En recrutement
- Registre
- NCT07514936
-
Étude A Multicenter, Prospective, Randomized Controlled Clinical Study Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in the Treatment of Adult Newly Diagnosed Early Precursor T-cell Acute Lymphoblastic Leukemia (ETP-ALL)
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06361329
-
Étude An Open-label, Clinical Study of CD7-targeted CAR-T Cells for the Treatment of Measurable Residual Disease of T-lymphoblastic Leukaemia/Lymphoma Post Allogeneic Stem Cell Transplantation
- Investigateur principal
- Xiao-Jun Huang · Chief
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT07280494
-
Étude A Multicenter Prospective Clinical Study of Inotuzumab Ozogamicin (INO) in the Treatment of Minimal Residual Disease Recurrent After Hematopoietic Stem Cell Transplantation of Acute Lymphoblastic Leukemia (ALL)
- Investigateur principal
- Sheng-Li Xue, MD · Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT05940961
-
Étude A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT04588922
-
Étude MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT07131059
-
Étude A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
- Investigateur principal
- He Huang · Clinical Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06633341
-
Étude Low-intensity Chemotherapy Combined With Targeted-Immunotherapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Prospective Clinical Cohort Study
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT07493161
-
Étude Clinical Study of CD5 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory T-Cell Hematologic Malignancies
- Hôpital
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Statut
- En recrutement
- Registre
- NCT06909474
-
Étude Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL
- Hôpital
- Ruijin Hospital
- Statut
- En recrutement
- Registre
- NCT06136364
-
Étude A Multicenter, Single-Arm Clinical Study of the Venetoclax, Ivosidenib, and Azacitidine Triple-Drug Regimen in the Treatment of Chemotherapy-eligible Adult Patients With IDH1-Mutated Acute Myeloid Leukemia.
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT06611839
-
Étude The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
- Investigateur principal
- Xianmin Song, MD · Doctor
- Hôpital
- Shanghai General Hospital
- Statut
- En recrutement
- Registre
- NCT06307054
-
Étude A Study of Chidamide With AZA in MRD Positive AML After Transplant
- Investigateur principal
- WENG Jian yu · professor
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- En recrutement
- Registre
- NCT06066905
-
Étude A Global Multicenter Open Label Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib vs Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06319456
-
Étude Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
- Investigateur principal
- Siqi Li · Chief Technician
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT07537738
-
Étude A Single-arm, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of U32 Injection in Patients With Acute Myeloid Leukemia.
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07036250
-
Étude Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia, a Prospective, Open, Multicenter, Randomized, Control Study (COMPLETE Study)
- Investigateur principal
- Xiao-Jun Huang · Prof.
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06581081
-
Étude Clinical Study on the Safety and Efficacy of Autologous Hematopoietic Stem Cell Transplantation Combined With BCMA-CAR-T in the Treatment of Ultra-high Risk Multiple Myeloma
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT07109323
-
Étude Clinical Study Protocol to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia
- Investigateur principal
- Donghua Zhang · Director
- Hôpital
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Statut
- En recrutement
- Registre
- NCT07237230
-
Étude A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
- Investigateur principal
- MEI HENG · Professor
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- En recrutement
- Registre
- NCT07470073
-
Étude Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Comparison to Consolidation Therapy Based Venetoclax for Elderly Patients With Acute Myeloid Leukemia After First CR
- Investigateur principal
- He Huang · Discipline Leader of Bone Marrow Transplant Center
- Hôpital
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Statut
- En recrutement
- Registre
- NCT06571825
-
Étude Study of the Efficacy and Safety of Venetoclax as Consolidation to Achieve Fix-Duration Treatment in CLL Patients Treated With BTK Inhibitor Monotherapy
- Hôpital
- Jiangsu Province Hospital
- Statut
- En recrutement
- Registre
- NCT06958705
-
Étude A Perspective, Multicenter, Open-label and Observational Trial for Unrelated Umbilical Cord Blood Stem Cell Microtransplantation Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and Secondary AML.
- Hôpital
- Jiangsu Province Hospital
- Statut
- En recrutement
- Registre
- NCT05584761
-
Étude The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine Versus Standard Chemotherapy or VA in the Treatment of Acute Myeloid Leukemia With High-risk, a Multicenter, Prospective, Randomized Study
- Hôpital
- Nanfang Hospital
- Statut
- En recrutement
- Registre
- NCT06810791
-
Étude The Safety and Efficacy of CD19 & CD22 Bispecific CAR T Cells in Treating Relapsed / Refractory B Cell Hematological Tumors
- Investigateur principal
- MEI HENG · Proferssor, Cheif Doctor
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- En recrutement
- Registre
- NCT06735495
-
Étude Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06381817
-
Étude A Prospective Cohort Study of a Pediatric-Inspired Chemotherapy Regimen Combined With Venetoclax and Immunotherapy for the Treatment of Adult Ph-Negative Acute Lymphoblastic Leukemia
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT07495631
-
Étude A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT05294731
-
Étude A Randomized, Controlled, Prospective Study on the Efficacy and Safety of Active Immunity Induced by Autologous Peptides for Maintenance Therapy in Acute Myeloid Leukemia (AML)
- Investigateur principal
- HuangMeiJuan · Clinical Professor
- Hôpital
- Fujian Medical University Union Hospital
- Statut
- En recrutement
- Registre
- NCT07551037
-
Étude Assessment of the Safety and Efficacy of Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia: A Single-Arm, Open-Label, Prospective Study
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06696833
-
Étude A Multicenter, Open-label, Prospective, Randomized Controlled Study to Optimize the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
- Investigateur principal
- Yehui Tan · Professor
- Hôpital
- The First Hospital of Jilin University
- Statut
- En recrutement
- Registre
- NCT07023588
-
Étude Reduced-dose Anti-thymocyte Globulin Plus Mini-dose Post-transplant Cyclophosphamide for GVHD Prevention in Haploidentical Donor HCT for Hematologic Malignancy
- Investigateur principal
- Xiao-Jun Huang · Peking University People's Hospital
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06984536
-
Étude Exposure-Response and Prognostic Analysis of Venetoclax Therapeutic Drug Monitoring in Newly Diagnosed AML
- Investigateur principal
- CHEN Jia · Chief Physician of Hematology. Clinical Professor. Principal Investigator
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07670130
-
Étude Clinical Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Investigateur principal
- Chunyan Sun · Professor
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- En recrutement
- Registre
- NCT06140966
-
Étude A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Hôpital
- Jiangsu Province Hospital
- Statut
- En recrutement
- Registre
- NCT07139873
-
Étude Haploidentical Combined With Cord Blood Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Prospective, Multicenter Clinical Study
- Hôpital
- Fujian Medical University Union Hospital
- Statut
- En recrutement
- Registre
- NCT07588360
-
Étude The Efficacy of Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Phase Ⅱ Multicenter Clinical Trial From China
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT06530576
-
Étude A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies
- Hôpital
- Henan Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07424833
-
Étude An Open-Label, Single-Arm, Phase II Exploratory Study of ABL and JAK Kinase Inhibitors With Chemotherapy and Venetoclax in Adult Patients With Ph-like ALL
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT07454226
-
Étude Cord Blood-derived CD70-targeting CAR-NK Cell Therapy for Refractory/Relapsed T Cell Lymphoma and Acute Myeloid Leukemia
- Hôpital
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Statut
- En recrutement
- Registre
- NCT06696846
-
Étude HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT05586074
-
Étude The Impact of Artificial Intelligence-Assisted Health Education on Patients' Intention to Participate in Clinical Trials: A Cluster-Randomised Controlled Trial
- Investigateur principal
- Fuling Zhou · Dean, School of Nursing, Wuhan University; Tenured Full Professor, Director of Department of Hematology, zhongnan Hospital,Wuhan University
- Hôpital
- Zhongnan Hospital of Wuhan University
- Statut
- En recrutement
- Registre
- NCT07305337
-
Étude The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
- Investigateur principal
- Shen yang · Chief physician
- Hôpital
- Ruijin Hospital
- Statut
- En recrutement
- Registre
- NCT06458257
-
Étude A Multicenter, Open, Dose Escalation and Dose Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT05947344
-
Étude A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT07743112
-
Étude CD180 CART Cell Injection in the Treatment of Relapsed or Refractory CD180 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT07106749
-
Étude Phase I Clinical Trial Protocol for Tolerability and Pharmacokinetics of TQB3455 Tablets in Patients With Hematological Malignancies
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06550713
-
Étude To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation：A Multicenter, Single-arm Study
- Hôpital
- Nanfang Hospital
- Statut
- En recrutement
- Registre
- NCT05270200
-
Étude A Prospective,Randomized,and Comparative Study on the Efficacy of Venetoclax Combined With CACAG Regimen and BAT Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Investigateur principal
- Daihong Liu · doctor
- Hôpital
- Chinese PLA General Hospital
- Statut
- En recrutement
- Registre
- NCT06084819
-
Étude A Phase 2, Multicenter, Single-arm, Open-label Study on the Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT06224257
-
Étude A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KSV01 Injection in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Investigateur principal
- He Huang · Clinical Professor
- Hôpital
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Statut
- En recrutement
- Registre
- NCT07246707
-
Étude An Open-label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR733 Cell Injection in Acute Myeloid Leukemia
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06234904
-
Étude An Exploratory Study on Targeted CD22/CD19 Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy for Enhanced Consolidation Therapy of Standard-risk B-cell Acute Lymphoblastic Leukemia
- Investigateur principal
- Liping Dou · Director
- Hôpital
- Chinese PLA General Hospital
- Statut
- En recrutement
- Registre
- NCT07575919
-
Étude Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
- Hôpital
- The First Affiliated Hospital of Xi'an Jiaotong University
- Statut
- En recrutement
- Registre
- NCT07503730
-
Étude Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia：Phrase II, Exploratory Study
- Hôpital
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Statut
- En recrutement
- Registre
- NCT07105579
-
Étude Clinical Trial for the Safety and Efficacy of CAR-T Cells Therapy for Patients With the Central Nervous System Involvement of Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia or B-cell Non-Hodgkin's Lymphoma
- Investigateur principal
- He Huang · Clinical Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT04532203
-
Étude PA3-17 Injection for the Treatment of Subjects With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma: A Single-Arm, Open-Label Phase II Clinical Trial
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07188610
-
Étude A Phase I Dose-Escalation and Phase II Study of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
- Investigateur principal
- Xiao-Jun Huang · Director of Peking University Institute of Hematology
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06880913
-
Étude Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for Relapsed/refractory Acute Myeloid Leukemia
- Investigateur principal
- Xiao-Ning Gao · Chief Physician
- Hôpital
- Chinese PLA General Hospital
- Statut
- En recrutement
- Registre
- NCT06741722
-
Étude A Phase 1, Open-label, Multicentre Study Evaluating the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Preliminary Efficacy of CG009301 for Injection in Adult Subjects With Relapsed or Refractory Haematological Malignancies
- Hôpital
- The First Affiliated Hospital of Nanchang University
- Statut
- En recrutement
- Registre
- NCT07347171
-
Étude A Phase I/II Single-center Study Evaluating the Safety and Efficacy of BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in Adults With Refractory/Relapsed B-cell Acute Lymphoblastic Leukaemia
- Investigateur principal
- Han weidong · Director of Biotherapeutic Department
- Hôpital
- First Hospital of China Medical University
- Statut
- En recrutement
- Registre
- NCT07008885
-
Étude A Prospective, Multicenter Clinical Study on The Safety and Efficacy of Avapritinib in The Treatment of Relapsed/Refractory Pediatric Core Binding Factor Acute Myeloid Leukemia (CBF-AML) With KIT Mutation
- Investigateur principal
- Shaoyan Hu · Study Chair
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT06316960
-
Étude The Efficacy and Safety of Third Generation Tyrosine Kinase Inhibitors Combined With Azacitidine and B-cell Lymphoma-2 Inhibitor in Patients With Myeloid Blast Phase Chronic Myeloid Leukemia
- Investigateur principal
- Qian Jiang · Professor
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06390306
-
Étude The Safety and Efficay Investigation of IL-5 CAR-T Cell Therapy for Patients With Refractory/Relapsed Eosinophilic Leukemia
- Investigateur principal
- He Huang · Clinical Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07257640
-
Étude The Efficacy and Safety of VA Alternating With Low-dose CHA in the Treatment of Newly Diagnosed Unfit AML: a Prospective, Multi-centers, Single Arm Phase II Study
- Investigateur principal
- Jie Sun · Principle Attending, Associated Professor
- Hôpital
- Beijing Chao-Yang Hospital, Capital Medical University
- Statut
- En recrutement
- Registre
- NCT07172204
-
Étude An Exploratory Clinical Study of CAR-T Cell Immunotherapy Using Polymer-lipid Particles to Deliver CAR1920 mRNA Targeting CD19/CD20 for Thetreatment of Relapsed/Refractory B-cell Lymphoma/Leukemia
- Investigateur principal
- Daihong Liu · Dr.
- Hôpital
- Chinese PLA General Hospital
- Statut
- En recrutement
- Registre
- NCT07321301
-
Étude Blinatumomab Sequential Donor Lymphocyte Infusion in Acute B Lymphocytic Leukemia Observation of Therapeutic Effect in Patients With Recurrence After Allogeneic Hematopoietic Stem Cell Transplantation
- Investigateur principal
- Suping ZHANG · visiting staff
- Hôpital
- First Affiliated Hospital of Zhengzhou University
- Statut
- En recrutement
- Registre
- NCT06339775
-
Étude A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19/CD22 CAR-T) in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
- Investigateur principal
- Rong Tao · Chief physician
- Hôpital
- The First Affiliated Hospital of Nanchang University
- Statut
- En recrutement
- Registre
- NCT06445803
-
Étude Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07284927
-
Étude A Phase Ib/II, Open-Label, Dose-Escalation and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PBSS1113 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Hôpital
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Statut
- En recrutement
- Registre
- NCT07761533
-
Étude A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT06656494
-
Étude Dose Escalation Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Decitabine and Cytarabine (D-CMG) for the Treatment of Elderly Newly Diagnosed Acute Myeloid Leukemia (AML) Patients
- Investigateur principal
- Bing, Xu · Principal Investigator
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06651866
-
Étude The First Affiliated Hospital, Zhejiang University School of Medicine
- Investigateur principal
- He Huang · The President of the First Affiliated Hospital, Zhejiang University School of Medicine
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06076226
-
Étude The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk Core-binding-factor Acute Myeloid Leukemia
- Investigateur principal
- Shen yang · Chief physician
- Hôpital
- Ruijin Hospital
- Statut
- En recrutement
- Registre
- NCT06458244
-
Étude A Multicenter, Single-Arm, Prospective Clinical Study of Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia
- Investigateur principal
- Xiao-Jun Huang · Prof.
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06869265
-
Étude An Early Exploratory Clinical Study of the Safety, Tolerability and Preliminary Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma/Leukaemia
- Investigateur principal
- Jia Wei · professor
- Hôpital
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Statut
- En recrutement
- Registre
- NCT06689917
-
Étude An Exploratory Study on the Safety and Efficacy of Luspatercept in the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia
- Investigateur principal
- Liang Zhao · Professor
- Hôpital
- Zhujiang Hospital of Southern Medical University
- Statut
- En recrutement
- Registre
- NCT07362095
-
Étude A Single-arm, Prospective Study of a Cladribine-Bridged Lisaftolax and Busulfan Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia in Elderly Patients
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07500753
-
Étude A Prospective, Multicenter, and Exploratory Study of Mitoxantrone Liposomes, Cytarabine and G-CSF Combined With Vineclavone in the Treatment ofRecurrent Adult AML and MDS-EB-2/Elder AML
- Hôpital
- Ruijin Hospital
- Statut
- En recrutement
- Registre
- NCT06329999
-
Étude Prospective Randomized Study of the Effectiveness and Safety of Chemotherapy Protocols Containing Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3)
- Investigateur principal
- HuangMeiJuan · Chief Physician
- Hôpital
- Fujian Medical University Union Hospital
- Statut
- En recrutement
- Registre
- NCT07561892
-
Étude Predicting Patient Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of Measurable Residual Disease (MRD) Assessment by Digital Polymerase Chain Reaction and Conventional MRD
- Investigateur principal
- Xiao-Jun Huang · Professor
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06211166
-
Étude A Single-Arm, Multicenter, Open-Label, Dose- Escalating and Expanding,Phase I/II Study of SKLB1028 Combined With "7+3" Standard Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Hôpital
- West China Hospital, Sichuan University
- Statut
- En recrutement
- Registre
- NCT05445154
-
Étude Study on the Efficacy and Safety of VMAC Combined With Donor Lymphocyte Infusion (DLI) in the Treatment of Patients With Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT06447090
-
Étude A Multi-center Prospective Single Arm Clinical Study of Prolonged Ultra Low-dose Decitabine Combined With Venetoclax (Bcl-2 Inhibitor) as First Line Treatment for Elderly Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes
- Investigateur principal
- Weiyan Zheng · Clinical Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06046313
-
Étude Super-universal CD7 CART (supCD7 CART) Cell Injection in the Treatment of Relapsed or Refractory CD7 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT07153068
-
Étude A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haploidentical Hematopoietic Stem Cell Transplantation Using a TBI or TMLI Conditioning Regimen for Pediatric Acute Lymphoblastic Leukemia
- Investigateur principal
- Xiangbo Wan · Professor
- Hôpital
- First Affiliated Hospital of Zhengzhou University
- Statut
- En recrutement
- Registre
- NCT06559345
-
Étude The Significance of Serum Ferritin in the Diagnosis, Differential Diagnosis, and Prognosis of Immune-related Adverse Event (irAE)
- Hôpital
- Tianjin Medical University Cancer Institute & Hospital
- Statut
- En recrutement
- Registre
- NCT06702566
-
Étude Safety and Efficacy of Universal Off-the-shelf CAR-NK Cells Targeted CD123 (JD123 Injection) in the Treatment of Refractory or Relapsed CD123-positive Acute Myeloid Leukemia
- Investigateur principal
- Xiao-Jun Huang · Professor
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06201247
-
Étude Exploratory Clinical Study of JAK1 Inhibitor Golidocitnib in the Treatment of Relapsed/Refractory Indolent T/NK-Cell Lymphomas：An Open, Prospective, Exploratory Clinical Trial
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT06716658
-
Étude A Single-Center, Prospective, Single-Arm Phase II Clinical Study of Consolidation With High-Dose Cytarabine Following Deep Molecular Remission Induced by Gilteritinib Plus VA Regimen in Newly Diagnosed Intermediate-Risk Fit AML Patients With FLT3-ITD Mutation
- Investigateur principal
- Jie Sun · Principle Attending, Associated Professor
- Hôpital
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Statut
- En recrutement
- Registre
- NCT07259707
-
Étude A Clinical Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for B-Cell Acute Lymphoblastic Leukemia(B-ALL) Patients in First Complete Remission (CR1)，Minimal Residual Disease(MRD) Positive
- Investigateur principal
- Jin Wang · chief physician, MD, PhD
- Hôpital
- Ruijin Hospital
- Statut
- En recrutement
- Registre
- NCT06718244
-
Étude Donor Derived CD117 CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Investigateur principal
- He Huang · Principal Investigator
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07144020
-
Étude CD123-Targeted CD16 Antibody-Modified NK Cell Immunotherapy for Refractory/Relapsed Acute Myeloid Leukemia (R/R AML)
- Investigateur principal
- Chunji Gao · Principal Investigator
- Hôpital
- Chinese PLA General Hospital
- Statut
- En recrutement
- Registre
- NCT06835140
-
Étude A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- En recrutement
- Registre
- NCT06880354
-
Étude CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial
- Investigateur principal
- LIANG WANG · Director of the department of hematology
- Hôpital
- Beijing Tongren Hospital
- Statut
- En recrutement
- Registre
- NCT06081478
-
Étude Prospective, Multicenter, Real-world Study of Dolasetron Mesylate Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children With Acute Lymphoblastic Leukemia
- Investigateur principal
- Tianping Chen · Associate chief physician
- Hôpital
- Anhui Provincial Children's Hospital
- Statut
- En recrutement
- Registre
- NCT06756022
-
Étude A Phase II/III Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06378138
-
Étude Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia: A Perspective Longitudinal Study
- Investigateur principal
- Dr Eva Ho · Associate professor
- Hôpital
- Henan Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07326930
-
Étude A Multicenter, Randomized, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06387069
-
Étude A Multicenter, Prospective, Single-Arm Study of Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Investigateur principal
- Bing, Xu · Dr. Bing Xu
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07783100
-
Étude A Clinical Study to Explore the Safety, Efficacy, and Pharmacokinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
- Statut
- En recrutement
- Registre
- NCT06718270
-
Étude Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
- Investigateur principal
- Shuhong Shen · Chair of hematology oncology department of SCMC
- Hôpital
- Anhui Provincial Children's Hospital
- Statut
- En recrutement
- Registre
- NCT06607419
-
Étude A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT06927466
-
Étude Safety and Efficacy Study of Demethylating Agents With Venetoclax in Preventing Recurrence of High-risk T-cell Lymphoblastic Lymphoma/Leukemia After Transplantation
- Investigateur principal
- Xianmin Song, MD · Professor
- Hôpital
- Shanghai General Hospital
- Statut
- En recrutement
- Registre
- NCT06686108
-
Étude A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Hôpital
- Peking Union Medical College Hospital
- Statut
- En recrutement
- Registre
- NCT06973187
-
Étude A Randomized, Controlled, Double-Blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of IMM01 (Timdarpacept) in Combination With Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT06647862
-
Étude Clinical Study on the Safety and Efficacy of CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
- Hôpital
- Guangzhou Women and Children's Medical Center
- Statut
- En recrutement
- Registre
- NCT06752785
-
Étude The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With Relapsed or Refractory B-lymphoblastic Leukemia
- Investigateur principal
- Xiaoyu Zhu · Chief Prof.
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT06307600
-
Étude A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination With Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in The Elderly
- Investigateur principal
- Yehui Tan · Professor
- Hôpital
- The First Hospital of Jilin University
- Statut
- En recrutement
- Registre
- NCT06990321
-
Étude Phase 2 Trial of Menin Inhibitor BN104 as Post Hematopoietic Stem Cell Transplantation Maintenance in Patients With Acute Leukemia
- Investigateur principal
- Chen Suning · Prof.
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07101497
-
Étude A Prospective, Randomized Controlled Clinical Study on the Efficacy and Safety of the TmBU Regimen Versus mBUCY Regimen for Conditioning Before Allo-HSCT in High-risk or Relapsed/Refractory Acute Leukemia
- Investigateur principal
- Sheng-Li Xue, MD · Prof.
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06816134
-
Étude A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT05924750
-
Étude Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia
- Investigateur principal
- Sun Yuqian · Principal Investigator
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT07588594
-
Étude A Novel Post-transplant Regimen of PT/FLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial
- Hôpital
- Nanfang Hospital
- Statut
- En recrutement
- Registre
- NCT06155188
-
Étude A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
- Hôpital
- Second Xiangya Hospital of Central South University
- Statut
- En recrutement
- Registre
- NCT05254743
-
Étude A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Hôpital
- Zhujiang Hospital of Southern Medical University
- Statut
- En recrutement
- Registre
- NCT06118788
-
Étude A Prospective, Multicenter, Randomized Controlled Study on the MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
- Hôpital
- First Affiliated Hospital of Zhengzhou University
- Statut
- En recrutement
- Registre
- NCT06345365
-
Étude A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Hôpital
- China-Japan Friendship Hospital
- Statut
- En recrutement
- Registre
- NCT06943872
-
Étude A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
- Hôpital
- Peking University First Hospital
- Statut
- En recrutement
- Registre
- NCT06852222
-
Étude A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Hôpital
- Shenzhen People's Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07676006
-
Étude Clinical Study on the Safety and Efficacy of QH101 in Patients With Relapsed/Refractory Acute Myeloid Leukemia(R/R AML) and Relapsed/Refractory Myelodysplastic Syndromes(R/R MDS)
- Investigateur principal
- Xiaoyu Zhu · Director of Hematology Department
- Hôpital
- Anhui Provincial Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07131085
-
Étude A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Blinatumomab in the Treatment of Adult de Novo Philadelphia Chromosome Positive Acute Lymphoid Leukemia
- Investigateur principal
- Chen Suning · Principal Investigator
- Hôpital
- First Affiliated Hospital of Soochow University
- Statut
- Pas encore en recrutement
- Registre
- NCT05931757
-
Étude Single-Arm, Multicenter, Prospective Phase II Clinical Study of Rituximab Combined With Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for Richter Syndrome Transformed From Chronic Lymphocytic Leukemia
- Hôpital
- Henan Cancer Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07831395
-
Étude Comparing the Efficacy and Safety of Decitabine-Fludarabine-busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as Conditioning Regimens for AML-MR
- Investigateur principal
- Hu Xiaoxia · Principal Investigator
- Hôpital
- Ruijin Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06297772
-
Étude A Prospective, Multicenter, Randomized Controlled, Open Label, Non-Inferiority Study Comparing the Efficacy and Safety of the VA Regimen (Venetoclax Combined With Azacitidine) With the "3+7" Regimen in the Treatment of Newly Diagnosed AML Patients With NPM1 or IDH1/IDH2 Mutations
- Investigateur principal
- Shen yang · Chief Physician, Professor, Department of Hematology
- Hôpital
- Ruijin Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07664839
-
Étude A Phase 1b/2 Study of AK117 (Anti-CD47 Antibody) in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- Pas encore en recrutement
- Registre
- NCT06387420
-
Étude A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
- Investigateur principal
- MEI HENG · Principal Investigator
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- Pas encore en recrutement
- Registre
- NCT07233018
-
Étude Effectiveness and Safety of Inotuzumab Ozogamicin±Donor Lymphocyte Infusion for Relapsed B Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation：Phrase II, Multicenter Study
- Investigateur principal
- Yi Luo · Clinical Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT06861348
-
Étude A Prospective, Multicenter, Open-label, Randomized Controlled Trial of SHR2554 Plus Azacitidine in Overlapped Sequential Combination With Modified BUCY Conditioning Regimen in Patients With High-risk or Relapsed/Refractory Acute Leukemia and Myelodysplastic Neoplasms Secondary IDs
- Investigateur principal
- Limin Liu,MD · Principal Investigator
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07575412
-
Étude Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Investigateur principal
- Donghua Zhang · professor
- Hôpital
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Statut
- Pas encore en recrutement
- Registre
- NCT07342244
-
Étude Assessment of the Safety and Efficacy of Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia: A Single-Arm, Open-Label, Prospective Study
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT06559644
-
Étude An Early Exploratory Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Investigateur principal
- He Huang · Professor, Director of the Bone Marrow Transplantation Center
- Hôpital
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Statut
- Pas encore en recrutement
- Registre
- NCT06902025
-
Étude Phase I Clinical Study of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) for the Treatment of Relapsed/Refractory CD19-positive B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Hôpital
- Ruijin Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06641024
-
Étude A Multicenter Prospective Study on Structuralized Follow-up Model Construction and Late Effect Burden of Childhood Hematological Malignancy Survivors (HEM-SURVIVE)
- Investigateur principal
- zhangjingying · Principal Investigator
- Hôpital
- Children's Hospital Zhejiang University School of Medicine
- Statut
- Pas encore en recrutement
- Registre
- NCT07483749
-
Étude A Single-Arm, Prospective Clinical Study of the Efficacy and Safety of VABu Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Non-High-Risk AML Patients in CR1 With Low Performance Status (ECOG ≥ 2) or High Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI ≥ 2)
- Hôpital
- First Affiliated Hospital of Soochow University
- Statut
- Pas encore en recrutement
- Registre
- NCT07762508
-
Étude An Exploratory Clinical Study Evaluating the Safety and Pharmacokinetic Profile of SNC116 in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Hôpital
- The First Hospital of Jilin University
- Statut
- Pas encore en recrutement
- Registre
- NCT07830238
-
Étude A Multicenter, Open-Label, Phase 1/2 Clinical Study of the Safety and Efficacy of Aclarubicin Combined With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
- Investigateur principal
- Junmin Li · Chief Physician of hematology
- Hôpital
- Ruijin Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07486726
-
Étude Efficacy and Safety of Maintenance Treatment With Chidamide, Venetoclax, and Azacitidine for Treatment-Naive Acute Myeloid Leukemia Patients Achieving Complete Remission: A Multicenter Study
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- Pas encore en recrutement
- Registre
- NCT07521124
-
Étude A Multicenter, Open, Single-arm Phase I Dose-escalation and Dose-expansion Clinical Study: Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of FXS0683 Tablets in Patients With Relapsed or Refractory Hematologic Malignancies.
- Hôpital
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Statut
- Pas encore en recrutement
- Registre
- NCT07616089
-
Étude A Prospective Study on the Efficacy and Safety of Venetoclax, Azacitidine, and Homoharringtonine (VAH) Combination as a Bridging Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Myeloid Leukemia
- Hôpital
- Ruijin Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07091006
-
Étude Efficacy and Safety of Zanubrutinib, Obinutuzumab, and Bendamustine (ZGB) Regimen for First-Line Treatment of Chronic Lymphocytic Leukemia: A Single-Arm, Prospective Study
- Investigateur principal
- Ou Bai, MD/PHD · Director
- Hôpital
- The First Hospital of Jilin University
- Statut
- Pas encore en recrutement
- Registre
- NCT07003464
-
Étude A Prospective, Open-Label, Single-Arm, Two-Cohort Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Bcl-2 Inhibitor Combined With Azacitidine in the Treatment of Newly Diagnosed Mixed Phenotype Acute Leukemia
- Investigateur principal
- Chen Suning · Doctor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07573670
-
Étude This is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
- Investigateur principal
- Xiao-Jun Huang · Prof.
- Hôpital
- Peking University People's Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06557304
Cette page ne partage que des informations d'études publiquement enregistrées. Elle ne recommande ni n'encourage la participation à une étude. La participation est entièrement volontaire et les risques d'un traitement non approuvé sont inconnus ; contactez directement l'hôpital pour les critères d'éligibilité et les détails du consentement éclairé.
Thérapies avancées : ce qui est autorisé et ce qui est en essai
Hôpitaux disposant d'un titre de spécialité clé nationale
Afficher les fiches des hôpitaux 21 hôpitaux avec un titre de spécialité clé
Chaque ligne est un hôpital titulaire d'un titre de spécialité clinique clé nationale dans une spécialité à laquelle cette maladie est rattachée. Il s'agit d'un relevé d'inscriptions publiées, non d'une recommandation ni d'un classement.
21 hôpitaux avec un titre de spécialité clé nationale correspondant.
Les valeurs rédigées en chinois sont citées telles que publiées par la source.
Ce que rapportent les patients
Chiffres agrégés uniquement : un résultat national cité avec sa source et l'année à laquelle il se réfère. Il ne s'agit ni d'un témoignage de patient ni d'une affirmation sur une personne.
Selon le rapport de National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023) : National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.
National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).
Source : National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Niveau A
Tous les thèmes de thérapie et d'accès
Questions sur cette maladie
Nous ne pouvons pas donner d'avis médical, mais nous pouvons répondre aux questions sur cette page et sur l'organisation d'un traitement en Chine.
Codes ICD
Afficher le tableau des codes 5 codes ICD
| Version | Code | Nom dans cette version |
|---|---|---|
| ICD-10-WHO | C91 | Lymphoid leukaemia |
| ICD-10-WHO | C92 | Myeloid leukaemia |
| ICD-10-WHO | C93 | Monocytic leukaemia |
| ICD-10-WHO | C94 | Other leukaemias of specified cell type |
| ICD-10-WHO | C95 | Leukaemia of unspecified cell type |
Les lignes sont les entrées ICD-10 de l'Organisation mondiale de la Santé (OMS) pour cette maladie, citées telles que publiées.
Source et preuve
- URL de la source
- https://www3.ha.org.hk/cancereg/tc/icd10.html
- Schéma de la source
- https
- Type de source
- Compilation tierce
- Niveau de preuve
- A - énoncé par une commission de la santé, un institut national de recherche ou une université
- Consultée le
- 2026-10-01